Leonard R. Henry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leonard R. Henry has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Stojadinovic
Uniformed Services University of the Health Sciences, Bethesda, MD, USA
3 shared publications - Aviram Nissan
The Surgical Oncology Laboratory, Department of Surgery, Hadassah-Hebrew University Medical Center, Mount Scopus, Jerusalem, Israel
1 shared publication D. Wattendorf
National Capital Area Breast Care Center, National Naval Medical Center, Bethesda, Maryland
1 shared publication- David Gur
Univ. of Pittsburgh (United States)
1 shared publication - Dee Dee Smart
Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
1 shared publication - Diego Vicente
Naval Med Ctr San Diego, Dept Surg, San Diego, CA 92134 USA
1 shared publication
Latest Publications
- 22 March 2012
- Published by Wiley in Journal of Surgical Oncology
- Vol. 105 (5) , 444-451
Translational advances regarding hereditary breast cancer syndromes
Approximately 5–10% of breast cancers may be inheritable, up to 90% of which are due to mutations in BRCA1 and BRCA2. A substantial minority are caused by non‐BRCA mutations, such as TP53, PTEN, STK11, CHEK2, ATM, BRIP1, and PALB2 mutations. This review highlights translational research advances with regard to the development of probabilistic models for hereditary breast cancer syndromes, the identification of specific genetic mutations responsible for these syndromes, as well as their testing and interpretations. J. Surg. Oncol. 2012; 105:444–451.
- 22 March 2012
- Published by Wiley in Journal of Surgical Oncology
- Vol. 105 (5) , 444-451
Translational advances regarding hereditary breast cancer syndromes
Approximately 5–10% of breast cancers may be inheritable, up to 90% of which are due to mutations in BRCA1 and BRCA2. A substantial minority are caused by non‐BRCA mutations, such as TP53, PTEN, STK11, CHEK2, ATM, BRIP1, and PALB2 mutations. This review highlights translational research advances with regard to the development of probabilistic models for hereditary breast cancer syndromes, the identification of specific genetic mutations responsible for these syndromes, as well as their testing and interpretations. J. Surg. Oncol. 2012; 105:444–451.
- Open Access
- 9 July 2010
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 8 (1) , 59
Axillary sentinel lymph node biopsy after mastectomy: a case report
Sentinel lymph node biopsy has been established as the preferred method for staging early breast cancer. A prior history of mastectomy is felt to be a contraindication.
- 9 July 2010
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 8 (1) , 59
Open AccessAxillary sentinel lymph node biopsy after mastectomy: a case report
Sentinel lymph node biopsy has been established as the preferred method for staging early breast cancer. A prior history of mastectomy is felt to be a contraindication.
- Open Access
- 10 August 2009
- Published by Springer Nature in BMC Surgery
- Vol. 9 (1) , 12
Development of a clinical decision model for thyroid nodules
Thyroid nodules represent a common problem brought to medical attention. Four to seven percent of the United States adult population (10–18 million people) has a palpable thyroid nodule, however the majority (>95%) of thyroid nodules are benign. While, fine needle aspiration remains the most cost effective and accurate diagnostic tool for thyroid nodules in current practice, over 20% of patients undergoing FNA of a thyroid nodule have indeterminate cytology (follicular neoplasm) with associated malignancy risk prevalence of 20–30%. These patients require thyroid lobectomy/isthmusectomy purely for the purpose of attaining a definitive diagnosis. Given that the majority (70–80%) of these patients have benign surgical pathology, thyroidectomy in these patients is conducted principally with diagnostic intent. Clinical models predictive of malignancy risk are needed to support treatment decisions in patients with thyroid nodules in order to reduce morbidity associated with unnecessary diagnostic surgery.
- 10 August 2009
- Published by Springer Nature in BMC Surgery
- Vol. 9 (1) , 12
Open AccessDevelopment of a clinical decision model for thyroid nodules
Thyroid nodules represent a common problem brought to medical attention. Four to seven percent of the United States adult population (10–18 million people) has a palpable thyroid nodule, however the majority (>95%) of thyroid nodules are benign. While, fine needle aspiration remains the most cost effective and accurate diagnostic tool for thyroid nodules in current practice, over 20% of patients undergoing FNA of a thyroid nodule have indeterminate cytology (follicular neoplasm) with associated malignancy risk prevalence of 20–30%. These patients require thyroid lobectomy/isthmusectomy purely for the purpose of attaining a definitive diagnosis. Given that the majority (70–80%) of these patients have benign surgical pathology, thyroidectomy in these patients is conducted principally with diagnostic intent. Clinical models predictive of malignancy risk are needed to support treatment decisions in patients with thyroid nodules in order to reduce morbidity associated with unnecessary diagnostic surgery.
- 9 February 2009
- Published by Wiley in Journal of Surgical Oncology
- Vol. 99 (6) , 319-323
The influence of a Gene expression profile on breast cancer decisions
Purpose: The Oncotype Dx® Recurrence Score (RS), is often employed in patients with estrogen receptor‐positive, node negative (ER+LN−) breast cancer. We investigated the impact of the RS on actual chemotherapy administration and the effect of the assay on a panel of breast oncology experts.Patients and Methods: The prospective adjuvant chemotherapy recommendations (prior to RS) and actual adjuvant therapy (after RS) for consecutive patients with ER+LN− breast cancer were recorded. After 6 months and with the same information, a panel of five experts made adjuvant therapy recommendations with and without RS and rated the strength of their recommendations. Rates of panel consensus, recommendation changes, and changes in recommendation strength were compared.Results: There were 29 patients (28 women). RS results altered the plan for chemotherapy in 9 patients (31%); 7 of 13 patients (54%) initially recommended for chemotherapy did not receive it, and 2 of 16 (13%) received chemotherapy following initial recommendations against it. RS results changed the panel's chemotherapy recommendation in 7 patients (24%): 5 of 12 (42%) recommendations for changed to against, and 2 of 17 (12%) recommendations against changed to for chemotherapy. RS increased consensus by the panel 10%, but did not increase the reported strength in chemotherapy recommendations.Conclusions: RS results were associated with real‐world decision changes in 31% of patients and 24% of panel recommendations and increased panel consensus by 10%. However RS did not increase the strength of panelist's recommendations. J. Surg. Oncol. 2009;99:319–323. Published 2009 Wiley Periodicals, Inc.
- 9 February 2009
- Published by Wiley in Journal of Surgical Oncology
- Vol. 99 (6) , 319-323
The influence of a Gene expression profile on breast cancer decisions
Purpose: The Oncotype Dx® Recurrence Score (RS), is often employed in patients with estrogen receptor‐positive, node negative (ER+LN−) breast cancer. We investigated the impact of the RS on actual chemotherapy administration and the effect of the assay on a panel of breast oncology experts.Patients and Methods: The prospective adjuvant chemotherapy recommendations (prior to RS) and actual adjuvant therapy (after RS) for consecutive patients with ER+LN− breast cancer were recorded. After 6 months and with the same information, a panel of five experts made adjuvant therapy recommendations with and without RS and rated the strength of their recommendations. Rates of panel consensus, recommendation changes, and changes in recommendation strength were compared.Results: There were 29 patients (28 women). RS results altered the plan for chemotherapy in 9 patients (31%); 7 of 13 patients (54%) initially recommended for chemotherapy did not receive it, and 2 of 16 (13%) received chemotherapy following initial recommendations against it. RS results changed the panel's chemotherapy recommendation in 7 patients (24%): 5 of 12 (42%) recommendations for changed to against, and 2 of 17 (12%) recommendations against changed to for chemotherapy. RS increased consensus by the panel 10%, but did not increase the reported strength in chemotherapy recommendations.Conclusions: RS results were associated with real‐world decision changes in 31% of patients and 24% of panel recommendations and increased panel consensus by 10%. However RS did not increase the strength of panelist's recommendations. J. Surg. Oncol. 2009;99:319–323. Published 2009 Wiley Periodicals, Inc.